SCHEMBL9895812

SCHEMBL9895812

CC(C)(C)OC(=O)NS(=O)(=O)c1ccc2ccccc2c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACACB O00763 1/20 0.61
KAT6A Q92794 5/20 0.58
L3MBTL1 Q9Y468 1/20 0.54
RAPGEF3 O95398 1/20 0.52
LARS1 Q9P2J5 1/20 0.51
ALDH1A1 P00352 3/20 0.49
LMNA P02545 2/20 0.49
GAA P10253 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
NLRP3 Q96P20 1/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
F2 P00734 1/20 0.48
PRSS1 P07477 1/20 0.48
PRSS2 P07478 1/20 0.48
PRSS3 P35030 1/20 0.48
PLAU P00749 1/20 0.47
POLB P06746 1/20 0.47
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26282598 0.85 RAPGEF3 (0.60) KAT6AL3MBTL1RAPGEF3LARS1ALDH1A1
SCHEMBL30549044 0.85 RAPGEF3 (0.60) KAT6AL3MBTL1RAPGEF3LARS1ALDH1A1
SCHEMBL5394506 0.82 CA1 (0.57) LARS1ALDH1A1GAACA12CA1
SCHEMBL17943496 0.81 L3MBTL1 (0.58) KAT6AL3MBTL1RAPGEF3LARS1ALDH1A1
SCHEMBL18019205 0.81 LARS1 (0.61) ACACBKAT6ARAPGEF3LARS1
SCHEMBL19792928 0.80 CA2 (0.53) ACACBKAT6ARAPGEF3LARS1ALDH1A1
SCHEMBL7299158 0.80 ACACB (0.60) ACACBKAT6AL3MBTL1ALDH1A1LMNA
SCHEMBL12550112 0.79 BCL2 (0.54) GAAMEN1KMT2ACA12CA1
SCHEMBL8889970 0.79 ACACB (0.66) ACACBKAT6AALDH1A1LMNAGAA
SCHEMBL8901368 0.79 ACACB (0.66) ACACBKAT6AALDH1A1LMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120148604-A1 TRP INHIBITORS AND USES THEREOF TRANSPOSAGEN BIOPHARMACEUTICALS, INC. (US) 2012-06-14 US disclosed
US-20120148604-A1 TRP INHIBITORS AND USES THEREOF TRANSPOSAGEN BIOPHARMACEUTICALS, INC. (US) 2012-06-14 US disclosed
US-20120148604-A1 TRP INHIBITORS AND USES THEREOF TRANSPOSAGEN BIOPHARMACEUTICALS, INC. (US) 2012-06-14 US disclosed
US-20080199807-A1 OPTICAL INFORMATION RECORDING MEDIUM, METHOD OF RECORDING INFORMATION AND METHOD OF USING COMPOUND FUJIFILM CORPORATION (JP) 2008-08-21 US disclosed
US-20080199807-A1 OPTICAL INFORMATION RECORDING MEDIUM, METHOD OF RECORDING INFORMATION AND METHOD OF USING COMPOUND FUJIFILM CORPORATION (JP) 2008-08-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120148604-A1 TRP INHIBITORS AND USES THEREOF TRPC4, TRPC1, TRPC3 ACACB 3596/4885KAT6A 3055/4885L3MBTL1 413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.